Recognitions

....................................................................................

 

SinoMab has received a number of recognitions including:

  1. 863 Program Project Grant awarded by The National High Technology Research and Development Program of China on “The Development of a Novel Bispecific Antibody Treatment Modality for Liver Cancer” (2001)

  2. A technology merit grant (US$ 65,000) awarded by the Department of Science and Technology of the Shenzhen Municipal Government on “The Development of a Novel Anti-lymphoma Antibody”.

  3. National 863 Program Antibody Engineering Sino-Hong Kong Cooperative Research Center since 2001 in collaboration with the Fourth Military Medical University, Xian.

  4. R&D project grant (RMB 500000) awarded by Science Industry Trade and Information Technology Commission of Shenzhen Municipality on “Novel Therapeutic Monoclonal Antibody” (2004)

  5. R&D project grant awarded by Shenzhen Nanshan Hi-tech Incubator (RMB 300000) in support of “The Establishment of a Platform for Developing Therapeutic Monoclonal Antibodies (2007)

  6. Financial Aid program (RMB 150000) for R&D activities for technology enterprises supported by Shenzhen Municipal Government (2008)

  7. R&D project grant (RMB 800000) awarded by Shenzhen Science and Technology Bureau on “Clinical Trials of a Therapeutic Monoclonal Antibody for Rheumatoid Arthritis and Other Auto-immunological Diseases” (2009)

  8. Innovation Fund for Technology Enterprises (RMB 800000) awarded by the National Ministry of Science and Technology of the People's Republic of China on “Clinical Trials of a Therapeutic Monoclonal Antibody against Lymphoma” (2009).

  9. Awarded National Science and Technology Major Projects (RMB 4,560,000) on “Major New Drugs Innovation and Development (China PR)” (2013-2015).

  10. Awarded National Science and Technology Major Projects (RMB 720,000) as part of the cooperation project grant on “Major New Drugs Innovation and Development” under the “Establishment of comprehensive technology platform for New drug development” (2013-2015)